



WEEKLY RADAR REPORT 02-27-22



Technical Market View

The **S&P 500 (SPX)** closed modestly higher last week after a wild, holiday-shortened week that saw us dip down to the lowest level since May 2021. We've been trading in a wide channel lower since the January highs and hit the channel bottom on Thursday morning, trading below the YTD value area which brought in strong responsive buying that brought back into range. A move higher back into the channel high would target further near-term upside to 4435. The next notable area of interest is 4492.5 which aligns with the November lows and the February VPOC. Momentum is starting to turn a bit as well with RSI out of a small pullback trend and MACD with a bullish cross and plenty of room to run off of oversold levels. A move lower has support at 4250 and then the 2/24 range has two notable high-volume nodes at 4166.75 and then 4137.50.



Market Sentiment/Breadth

All Sentiment for the week ending 2/23 saw bullish responses rise to 23.4% vs 19.2% prior and neutral sentiment fall to 22.9% from 37.6%. Bearish responses rose to 53.7% from 43.2%, close to a 9-year high while optimism remain well below historical levels. NAAIM Exposure fell to 44.41 from 53.49 prior and below 45 for the first time since May 2021. Lipper Fund flows had \$254M of inflows to equities and the third week of positive flows. As of Friday's close we had 88 new highs versus 122 new lows, much more moderate breadth than in the past two weeks. The percentage of stocks above their 50-MA was 29.6% while those above their 200-day was 27.8%. NYSE Summation remains muted at -724.39 and below its 8-EMA while NASI is back below its 8-EMA after crossing under this week. Cumulative AD remains in a bear trend. NYMO was -34.19, a neutral reading. CBOE Equity P/C 50-day MA was 0.67, a neutral reading. CNN Fear and Greed was 31 and down from 39 prior.

Seasonality Outlook

Per the Trader's Almanac,

- Final trading day of February has been up 51% of years since 1980 but weaker since 2000, up just 33% of years for the S&P.
- First trading day in March, S&P up 16 of the last 22 years, 73% win rate.
- S&P March returns the last 21 years have been 12 up, 9 down, 6th best month. Avg gain +0.7%.
- March returns for S&P during midterm election years averages +1.1%.

Below shows the daily odds the market has been up each day since the year 2000. The final trading day of the month has tended to be quite weak with the S&P showing bullish bias just 33% of the years since 2000. But early March has seen strength that lasts into mid-month which is followed by late-month weakness after St Patrick's Day. The second week of March shown below has generally had an upside bias especially towards the end of the week with the S&P the stronger index overall. Looking ahead to March OPEX week shows a stronger bullish bias heading into the quad witching expiration.

Seasonality Percentages <small>since year 2000</small>						
	Monday	Tuesday	Wednesday	Thursday	Friday	Weekly Avg
	2/28/2022	3/1/2022	3/2/2022	3/3/2022	3/4/2022	
Dow	33.3	61.9	38.1	61.9	47.6	48.6
S&P	33.3	71.4	38.1	66.7	52.4	52.4
Nasdaq	28.6	66.7	38.1	61.9	42.9	47.6
Average	31.7	66.7	38.1	63.5	47.6	49.5
	Monday	Tuesday	Wednesday	Thursday	Friday	Weekly Avg
	3/7/2022	3/8/2022	3/9/2022	3/10/2022	3/11/2022	
Dow	47.6	47.6	61.9	47.6	57.1	52.4
S&P	47.6	47.6	61.9	52.4	61.9	54.3
Nasdaq	33.3	47.6	52.4	47.6	61.9	48.6
Average	42.8	47.6	58.7	49.2	60.3	51.7

Market Event Outlook

Monday: Chicago PMI, Dallas Fed, Wholesale Inventories; **International Data:** Japan Retail Sales, Japan Industrial Production, Australian Retail Sales; **International Earnings:** Osram Licht; **Earnings Before the Open:** ASTE, WHD, CWEN, XRAY, DEA, HSKA, HNI, ITRI, JLL, RIDE, EYE, NLSN, RETA, TGNA, VTRS; **Earnings After the Close:** DDD, AAON, ACHC, ACAD, AMBA, BIGC, DAR, ENDP, FATE, FGEN, FRPT, GDRX, GRPN, HLIO, HRTX, HPQ, JRVR, LCID, MRTX, NKTR, NVAX, OSH, OKE, PDCE, PRAA, PRIM, PGNV, PUBM, SAIL, SBAC, SEER, SDC, SRI, SUPN, TASK, TREX, TPTX, VLDR, VRM, WDAY, ZM; **Conferences:** BMO Metals & Mining (KGC, EXK, NAK, EGO, AGI, MAG, NG, LAC, AUY, MP, AA, USAS, X, NGD, BMO, AEM, BTG, GOLD, BHP, CCI, CLF, EDR, FNV, FCX, NUE, NTR, OR, PAAS, RGLD, TECK, TRQ, VALE, WPM, HL, CDE, ASTL)

Tuesday: Manufacturing PMI, ISM Manufacturing, Motor Vehicle Sales, Fed's Bostic Speaks; **International Data:** RBA Meeting, Australian Manufacturing PMI, China Manufacturing PMI, EU Manufacturing PMI, German Manufacturing PMI, Italian GDP, UK Manufacturing PMI; **International Earnings:** Bayer, Flutter, Zalando, Covestro, Hello Fresh; **Earnings Before the Open:** GOLF, AMRN, AMRS, APG, AZO, BIDU, BMO, BNS, BSY, BLDR, CLVT, CRON, DPZ, EHTH, EPZM, EVRI, FSS, GCP, HTA, HGV, HZNP, HRL, TWNK, TILE, IGT, ITCI, SJM, KSS, KTB, MANU, MLCO, NFE, NOV, PRGO, RDNT, SE, FOUR, SHC, TGT, TMX, TRS, WEN, XHR; **Earnings After the Close:** DIBS, AKA, AMC, ARLO, BGS, BNFT, CDLX, CELH, CERT, CCXI, DOMO, BROS, FSLR, GO, GRWG, HCAT, HPE, INO, INSG, IPAR, JAMF, JAZZ, NSTG, JWN, PETQ, PLBY, PLUG, RGNX, RPAY, ROST, CRM, SRPT, SGMS, SOFI, TTEC, URBN, VUZI, WISH, WW, ZIP, ZGNX; **Analyst Days:** ACVA, KEY, TWNK, ADT, ETN, PGR, CVX, SLAB, ARLO; **Conferences:** BMO Metals & Mining

Wednesday: Chairman Powell Testifies in House, ADP Employment, Fed's Evans and Bullard Speak; **International Data:** Eurozone CPI, BOC Meeting; **International Earnings:** Naspers, Sberbank, Just Eat Takeaway; **Earnings Before the Open:** ANF, DIN, DLTR, DCI, DY, HAYW, PDCO, STER; **Earnings After the Close:** AEO, PLAN, BOX, AI, CHPT, CPNG, DSGX, FLYW, GEF, JXN, NTN, OKTA, PSTG, RSI, SGFY, SNOW, SPLK, VEEV, VSCO, ZUO; **Analyst Days:** C, XOM, SPR; **Conferences:** BMO Metals & Mining, BAML Ag and Materials (UNVR, LAC, IP, WCN, WRK, ESI, FMC, ATR, RSG, GPPE, GPP, AVY, PKG, WM, PCH, BLL, LYB, ADM, CF, NTR, ORGN, CTVA)

Thursday: Chairman Powell Testifies in Senate, Services PMI, ISM Services, Durable Goods, Fed's Williams Speaks; **International Data:** Japan Services PMI, Eurozone PPI, Eurozone Unemployment, ECB Minutes; **International Earnings:** Entain, Lufthansa; **Earnings Before the Open:** BBY, BIG, BILI, BJ, BF-B, BURL, CNQ, CPG, GMS, GOGO, HLLY, KR, MTL, TTC, TD, UTZ, WB; **Earnings After the Close:** AVAV, AQN, AVGO, COO, COST, DUOL, ESTC, EOLS, FNKO, GPS, GDYN, MRVL, NCMI, PBYI, SWBI, VZIO; **Analyst Days:** AWI, PLTK, DKN, LOGI, NEX, HON, ZION, CABO; **Conferences:** Credit Suisse Healthcare, BAML Ag and Materials, Susquehanna Tech (NATI, POWI, KN, AMD, NTAP, AEIS, LITE, WDC, XPRO, GLW, DAVA, HIMX, SSU, ZD, DIOD, KLAC, ACLS, VIAV), Berenberg Industrial Tech (DDD, AEIS, LIDR, AMBA, ARBE, AVY, BMI, CRNC, AQUA, FARO, GGG, INVZ, IGP, MKSI, OUST, REE, ST, VLDR, VIAO, ZBRA)

Friday: Employment Report; **International Data:** Eurozone Retail Sales, German Trade Balance, German Construction PMI, Italian GDP, UK Auto Registrations; **International Earnings:** Dassault Aviation; **Earnings Before the Open:** HIBB; **Analyst Days:** KR; **Conferences:** BAML Ag and Materials, Susquehanna Tech, Berenberg Industrial Tech

Insider Trade of the Week

Mohawk (MHK) with a large open market buy on 2/24 from the President and COO Christopher Wellborn of 10,000 shares at \$135.75, a more than \$1.3M investment. This is the first open market buy since March 2020 and first by a non-director since 2018. MHK is down 20% for the year and more than 37.5% off of 52-week highs. Shares are back at a high-volume node from 2019 and hammering last week off the 50% retracement of the rally from the March 2020 lows. The \$9.68B company trades 8.35X earnings, 0.86X sales, and 8.45X FCF with low leverage. MHK makes flooring products for remodeling and new constructions of residential and commercial spaces in the US and abroad. The company is a market leader in ceramic tiles, carpet and rugs, LVT, laminate, and many other categories with an expanding international footprint. MHK has seen record sales volumes across most categories and geographies while benefitting from higher pricing and a better mix of high-margin tile which is helping offset some of the rising inflation and supply chain constraints. Raymond James lowered estimates on 2/14 but keeps a Strong Buy on shares noting that it remains their favorite housing related name in light of its mix of professionally installed products, under-levered balance sheet, and again highly attractive valuation. Short interest is 1.8%.

Weekly Open Interest Radar

Southern Copper (SCCO) shares flagging on the weekly timeframe below \$70 and potential to push out of a wide multi-month base and make a run back at the 2021 highs near \$85. SCCO made a strong run in 2020 and the pullback has found support at the 38.2% Fibonacci of the move. SCCO has bullish open interest that is supportive of a continued move higher. On 1/7, the January 2024 \$60 ITM calls were bought 1500X for \$11 while the September \$80 calls were bought 1000X on 2/10.

Trade to Consider: Long the **SCCO** June \$70/\$80 Call Spread for \$3.25 or Better

Date	Description	Volume	Open.Int	Price	Delta	Impl Vo	Prob.ITM	Premium Paid
2/10/2022	SCCO 100 16 SEP 22 80 PUT	350	0	\$17.10	-1		100.00%	\$598,500
2/10/2022	SCCO 100 16 SEP 22 80 CALL	1,007	8	\$2.90	0		0.00%	\$292,030
1/7/2022	SCCO 100 19 JAN 24 60 CALL	1,524	45	\$11.00	0		0.00%	\$1,676,400
5/28/2021	SCCO 100 20 JAN 23 50 PUT	1,444	548	\$6.20	-0.207	43.13%	41.56%	\$895,280

Weekly Options Technical Trade Set-Up

Ticker	SNAP
Trigger Level	\$40
Call/Put	Calls
Strike	\$40
Target	\$43.75
Stop	\$38




Credit Spread of the Week

Social Name Beaten up into Key Long Term Volume Support

Twitter (TWTR) - The tech correction has put a lot of stocks into longer term support zones based on volume profile nodes of interest and TWTR specifically has fallen from nearly 70 just in October to as low as 32 this past week. The low 30s in TWTR represent solid long-term support and if waiting to get long some of the social communications names this could be the time to start scaling into positions into recent panic. TWTR tested its prior years VPOC near 33 into recent weakness and from a probability odds stance it looks like a great risk reward to at least snapback towards its 21-week EMA in the coming months north of 40. With implied volatility elevated, going out to April or further offers a nice opportunity to sell rich put premiums as the stock hammers out a floor. Selling the naked puts has the best probability if willing to own stock at expiration and with the next earnings report not due till after April options expire it should benefit from IV crush and theta burn. Options flows agree as TWTR saw a large opening put sale on 2/24 for 4500 contracts of the August \$32 short puts at \$4.10 for over \$1.8M in premium. Opening put sellers were also active on 2/24 for massive sales in August \$30 puts, July \$30 and \$32 puts. All combined over \$7.6M in net put premium sold.

Trade to consider: Sell TWTR April 35/32 bull put spread for \$1.10 credit or better. Alternatively, you can sell the April 33 put for \$1.50 if comfortable with naked risk and higher probability.



Earnings Preview

Costco (COST) reporting earnings on 3/3 after the close with the Street looking for \$2.75 on \$51.3B in sales. Next quarter is guided to \$2.95/\$49.1B while the FY is at \$12.89/\$218.9B, an 11.7% increase Y/Y. Shares have closed higher the last two but lower in five of the last eight overall. The average closing move is 1.35% while the max move was 6.58%. The current implied move is 2.65%. Shares are forming a nice consolidation and double-bottom above the rising 200-MA with a breakout above \$530 targeting the prior highs near \$565. Support is lower near \$468. The \$230.5B company trades 36.5X earnings, 1.15X sales, and 17X cash with a small yield. Short interest is 1%. December comps were strong with traffic elevated while January saw a re-acceleration on a 2-year stack basis. COST continues to see growth across core categories like food and sundries while other areas like healthy and beauty and apparel have improved. COST likely continues to see comps normalize back towards pre-COVID levels but moving forward in 2022 and beyond with a larger membership base which will continue to provide support. Baird was impressed by the January comps noting that traffic

gains remain impressive, its category strength was again broad-based, and its membership base has never been stronger, even though the stock still trades at a lofty valuation. MSCO with an interesting note on 2/7 suggesting the company is laying the groundwork for a CEO change based on a recent filing while another potential catalyst is the next membership fee increase which may come as soon as June/July. Hedge fund ownership fell 4.5%. COST options have been mixed lately but does have 3,750 March \$500 short puts in OI from 1/15.

Date	Description	Volume	Open.In	Price	Deltz	Impl Vo	Prob.ITN	Premium Pai
2/17/2022	COST 100 15 JUL 22 470 PUT	319	137	\$18.20	-0.27	29.00%	34.03%	\$577,390
2/11/2022	COST 100 19 JAN 24 365 PUT	250	0	\$19.65	-0.158	29.24%	27.83%	\$491,250
2/3/2022	COST 100 18 MAR 22 510 PUT	2,079	167	\$14.46	-0.4	27.28%	43.36%	\$3,066,525
2/3/2022	COST 100 18 MAR 22 550 CALL	2,128	605	\$7.40	0.28	25.72%	25.10%	\$1,659,840
2/2/2022	COST 100 15 JUL 22 480 PUT	636	58	\$19.80	-0.301	26.62%	36.62%	\$1,259,280
1/31/2022	COST 100 (Weeklys) 4 MAR 22 545 CALL	871	14	\$3.60	0.17	26.52%	15.54%	\$313,560
1/27/2022	COST 100 14 APR 22 470 PUT	1,335	181	\$21.29	-0.4	30.45%	45.95%	\$2,876,925
1/27/2022	COST 100 14 APR 22 465 PUT	1,368	78	\$19.41	-0.38	30.86%	43.10%	\$2,681,280
1/18/2022	COST 100 18 MAR 22 500 PUT	1,922	1,087	\$24.20	-0.53	26.48%	56.88%	\$4,756,950
1/18/2022	COST 100 18 MAR 22 575 CALL	1,851	172	\$2.21	0.09	27.10%	7.31%	\$407,220
1/5/2022	COST 100 18 MAR 22 535 PUT	627	25	\$12.40	-0.32	23.67%	35.69%	\$824,505
1/3/2022	COST 100 17 JUN 22 375 CALL	644	312	\$189.30	0.91	44.20%	88.80%	\$12,190,920

Top 40 Micro-Cap Profile

PROCEPT BioRobotics (PRCT) shares rallied 11% last week to get back near flat YTD and will next report earnings on 3-8 with the medical device industry showing recent relative strength as a latter stage reopening trade and a lot of recent news coverage on how cancer and other diseases are seeing increased death rates from delayed treatments.

PROCEPT is a commercial-stage surgical robotics company focused on advancing patient care by developing transformative solutions in urology. Its AquaBeam Robotic System is an advanced, image-guided, surgical robotic system for use in minimally-invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia, or BPH. BPH is the most common prostate disease and impacts approximately 40 million men in the United States. Effective in 2021, all local Medicare Administrative Contractors, or MACs, which represent 100% of eligible Medicare patients, issued final positive local coverage determinations to provide Medicare beneficiaries with access to Aquablation therapy in all 50 states.

BPH refers to the non-malignant enlargement of the prostate gland, a small gland in the male reproductive system, and in the United States is the number one reason men visit a urologist. BPH is estimated to occur in more than 50% of men in their 50s, growing to 70% of men in their 60s, and is the fourth most common diagnosed disease in men above 50 years old, ranking behind coronary artery disease, hypertension and type 2 diabetes. BPH often results in uncomfortable LUTS, which can have a significant impact on quality of life. If left untreated, BPH may eventually lead to more serious complications.

PRCT's total addressable patient population in the United States includes approximately 8.2 million patients, comprised of 6.7 million receiving drug therapy, 1.1 million who have tried but failed drug therapy and 400,000 undergoing surgical intervention each year. Based on the average selling price of its single-use handpiece, PRCT estimates a total addressable market opportunity in excess of \$20 billion in the United States. The global incidence of BPH among men over 50 years old is similar to that of the United States, representing a significant incremental market opportunity outside of the United States.

PRCT has a market cap of \$1.11B and trades 16X FY22 estimated EV/Sales with revenues growing 330% in 2021 and seen rising 53% in 2022 and 110% in 2023. Based on FY25 sales forecasts PRCT trades around 3.5X Sales. PRCT is coming off a strong report with a major jump in utilization, a strong leading indicator showing strong adoption for its robotic device.

PRCT carries the risk of long duration stocks with profitability remaining far out into the future but it has a superior technology, strong adoption trends, positive reimbursement and a large niche opportunity that certainly makes it an attractive M&A target for a larger medical device company looking to increase its presence in the growing theme of robotics.

March 4th (W) OpEx Notable Open Interest

Date	Description	Volume	Current	Current Price	Price Change	Current Value	OI Differential
1/31/2022	AAPL 100 (Weeklys) 4 MAR 22 185 PUT	10,686	10,097	\$17.70	-26.97%	\$17,871,690.00	-5.79%
2/18/2022	TSLA 100 (Weeklys) 4 MAR 22 800 PUT	2,550	2,657	\$56.00	102.53%	\$14,879,200.00	-38.67%
2/14/2022	TSLA 100 (Weeklys) 4 MAR 22 750 PUT	1,307	2,544	\$30.00	184.36%	\$7,632,000.00	34.89%
2/16/2022	SNAP 100 (Weeklys) 4 MAR 22 44 PUT	1,502	10,031	\$6.40	30.61%	\$6,419,840.00	561.24%
1/25/2022	AAPL 100 (Weeklys) 4 MAR 22 160 PUT	1,189	8,918	\$3.30	51.40%	\$2,942,940.00	508.32%
2/23/2022	SE 100 (Weeklys) 4 MAR 22 126 PUT	1,500	1,524	\$11.60	31.82%	\$1,767,840.00	-0.33%
2/17/2022	MRVL 100 (Weeklys) 4 MAR 22 71 CALL	7,420	5,498	\$2.32	-47.87%	\$1,275,536.00	-26.99%
1/31/2022	VFC 100 (Weeklys) 4 MAR 22 64 PUT	1,000	1,938	\$6.34	145.74%	\$1,228,692.00	-1.77%
1/31/2022	AMC 100 (Weeklys) 4 MAR 22 16 PUT	2,597	7,751	\$1.54	-35.29%	\$1,193,654.00	166.63%
2/24/2022	OPEN 100 (Weeklys) 4 MAR 22 9 CALL	4,028	4,028	\$2.90		\$1,168,120.00	
2/7/2022	AMD 100 (Weeklys) 4 MAR 22 112 PUT	2,546	1,900	\$5.73	167.76%	\$1,088,700.00	-30.50%
1/21/2022	UBER 100 (Weeklys) 4 MAR 22 40 PUT	1,000	1,441	\$7.43	38.88%	\$1,070,663.00	-16.12%
2/24/2022	AMZN 100 (Weeklys) 4 MAR 22 3000 CALL	1,003	1,003	\$8.80		\$882,640.00	
1/28/2022	CNC 100 (Weeklys) 4 MAR 22 80 CALL	2,059	3,025	\$2.86	10.00%	\$865,150.00	40.31%
2/14/2022	MRVL 100 (Weeklys) 4 MAR 22 65 PUT	1,326	1,938	\$4.36	30.54%	\$844,968.00	0.31%
2/16/2022	LLY 100 (Weeklys) 4 MAR 22 240 PUT	1,302	1,430	\$5.30	45.21%	\$757,900.00	6.72%
2/24/2022	PYPL 100 (Weeklys) 4 MAR 22 100 CALL	1,668	1,668	\$4.30		\$717,240.00	
2/24/2022	BA 100 (Weeklys) 4 MAR 22 200 CALL	2,503	2,503	\$2.65		\$663,295.00	
1/28/2022	BA 100 (Weeklys) 4 MAR 22 200 CALL	1,120	1,538	\$4.02	-23.72%	\$618,276.00	18.31%
1/28/2022	BBWI 100 (Weeklys) 4 MAR 22 53 PUT	1,501	1,501	\$3.75	0.00%	\$562,875.00	0.00%
2/15/2022	GPS 100 (Weeklys) 4 MAR 22 15.5 PUT	2,947	2,676	\$2.10	89.19%	\$561,960.00	-14.45%
1/26/2022	BBWI 100 (Weeklys) 4 MAR 22 49 PUT	3,000	2,151	\$2.52	254.93%	\$542,052.00	-28.30%
2/23/2022	KSS 100 (Weeklys) 4 MAR 22 54 CALL	3,020	2,115	\$2.27	-14.34%	\$480,105.00	-30.20%
2/23/2022	EOG 100 (Weeklys) 4 MAR 22 110 CALL	1,001	1,123	\$3.98	-7.44%	\$446,954.00	7.16%
2/18/2022	DKNG 100 (Weeklys) 4 MAR 22 21 PUT	2,095	2,119	\$2.00	-27.27%	\$423,800.00	-7.18%
2/11/2022	DKNG 100 (Weeklys) 4 MAR 22 23 PUT	1,236	1,258	\$3.35	59.52%	\$421,430.00	-30.73%
2/18/2022	AA 100 (Weeklys) 4 MAR 22 78 CALL	1,860	2,066	\$2.00	-42.03%	\$413,200.00	9.78%
1/18/2022	ABBV 100 (Weeklys) 4 MAR 22 140 PUT	1,036	7,112	\$0.55	91.20%	\$391,160.00	586.49%
1/31/2022	DLTR 100 (Weeklys) 4 MAR 22 123 PUT	1,089	1,052	\$3.65	0.00%	\$383,980.00	-3.40%
2/24/2022	C 100 (Weeklys) 4 MAR 22 61 CALL	2,418	2,418	\$1.55		\$374,790.00	
1/25/2022	COP 100 (Weeklys) 4 MAR 22 90 CALL	1,750	2,018	\$1.70	36.80%	\$343,060.00	11.00%
2/23/2022	DKNG 100 (Weeklys) 4 MAR 22 19 PUT	5,128	3,778	\$0.88	17.33%	\$332,464.00	-43.75%
2/16/2022	BYM 100 (Weeklys) 4 MAR 22 66 PUT	6,097	10,149	\$0.32	-33.33%	\$324,768.00	64.81%
2/15/2022	QCOM 100 (Weeklys) 4 MAR 22 145 PUT	1,700	2,596	\$1.23	32.26%	\$319,308.00	39.49%
1/28/2022	BA 100 (Weeklys) 4 MAR 22 210 CALL	1,220	2,578	\$1.21	57.09%	\$311,938.00	80.28%
1/31/2022	BA 100 (Weeklys) 4 MAR 22 210 CALL	2,167	2,578	\$1.21	76.27%	\$311,938.00	-20.58%

Disclaimer:

Not Investment Advice or Recommendation

Any descriptions "to buy", "to sell", "long", "short" or any other trade related terminology should not be seen as a recommendation. The Author may or may not take positions in any of the names mentioned, and is not obligated to disclose positions, nor position sizes.

Content is for informational and educational purposes only, and is not to be construed as specific investment advice or recommendations. You alone will need to evaluate the merits and risks associated with the use of this content. Decisions based on information provided are your sole responsibility, and before making any decision on the basis of this information, you should consider (with or without the assistance of a financial and/or securities adviser) whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. Investors should seek qualified professional financial advice regarding the suitability of investing in any securities or following any investment strategies.

No reference to any specific security constitutes a recommendation to buy, sell or hold that security or any other security. Nothing constitutes investment advice or offers any opinion with respect to the suitability of any security, and the views expressed on this website should not be taken as advice to buy, sell or hold any security. In preparing the information contained in this website, OptionsHawk has not taken into account the investment needs, objectives and financial circumstances of any particular investor. This information does not consider the specific investment objectives, financial situation and particular needs of any specific recipient of this information and investments discussed may not be suitable for all investors

Please see full legal disclaimer and terms of the subscription agreement for further details:

Note: Any attempt to copy or forward contents of this email is a violation of your subscriber agreement and can result in termination without refund. Please note your subscriber agreement makes you legally liable for any copyright infringement.